Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
- Conditions
- Soft Tissue SarcomaSarcomaNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasms
- Interventions
- First Posted Date
- 2005-02-01
- Last Posted Date
- 2013-01-10
- Target Recruit Count
- 41
- Registration Number
- NCT00102609
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- First Posted Date
- 2004-09-03
- Last Posted Date
- 2012-07-02
- Target Recruit Count
- 40
- Registration Number
- NCT00002904
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇩🇪Martin Luther Universitaet, Halle Saale, Germany
🇩🇪Universitats-Krankenhaus Eppendorf, Hamburg, Germany
Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
- Conditions
- Brain and Central Nervous System TumorsEndometrial CancerGastrointestinal Stromal TumorOvarian CancerSarcomaSmall Intestine Cancer
- First Posted Date
- 2004-06-03
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 132
- Registration Number
- NCT00003939
Ecteinascidin 743 in Treating Children With Refractory Solid Tumors
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-04-26
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 13
- Registration Number
- NCT00006463
- Locations
- 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸State University of New York - Upstate Medical University, Syracuse, New York, United States
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00005625
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00017030
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
- Conditions
- Malignant Mesothelioma
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- PharmaMar
- Registration Number
- NCT00027508
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
- First Posted Date
- 2003-11-11
- Last Posted Date
- 2014-04-08
- Target Recruit Count
- 59
- Registration Number
- NCT00072670
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
- Conditions
- Recurrent Ewing SarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaPeripheral Primitive Neuroectodermal Tumor
- Interventions
- Other: pharmacological study
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 50
- Registration Number
- NCT00070109
- Locations
- 🇺🇸
Childrens Memorial Hospital, Chicago, Illinois, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
- First Posted Date
- 2003-05-19
- Last Posted Date
- 2014-09-08
- Target Recruit Count
- 271
- Registration Number
- NCT00060944
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.